KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

Mannkind (MNKD) Short-Term Debt repayments (2018 - 2019)

Mannkind (MNKD) reported Short-Term Debt repayments of $4.4 million for Q3 2019, up 47.33% on a QoQ basis from $3.0 million in Q4 2018.

Mannkind (MNKD) has 2 years of Short-Term Debt repayments data on file, last reported at $4.4 million in Q3 2019.

  • Quarterly Short-Term Debt repayments changed N/A year-over-year to $4.4 million in Q3 2019, while the trailing twelve-month figure through Dec 2021 was $4.4 million (changed N/A YoY) and the FY2021 annual result came in at $10.0 million, changed N/A from the prior year.
  • Short-Term Debt repayments improved to $4.4 million in Q3 2019 per MNKD's latest filing, from $3.0 million in the prior quarter.
  • Across five years, Short-Term Debt repayments topped out at $4.4 million in Q3 2019 and bottomed at $3.0 million in Q4 2018.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Short-Term Debt repayments (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 102,000.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Mannkind 1.09 Bn 956.66 Mn 82.66 Mn -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2019 4.42 Mn
Sep 30, 2019 4.42 Mn
Dec 31, 2018 3.00 Mn
Dec 31, 2018 3.00 Mn